

Contact: David Fung, PhD
773.791.7913
www.nytmt.com
david.fung@nytmt.com

Industry: Pharma

Management:

Herb Sun, PhD; Former Professor of Surgery, Albert Einstein College of Medicine – Founder, CEO and President

Daniel Leong, PhD (Biomedical Engineering) – Chief Strategy Officer

David Fung, PhD (Biomedical Engineering) – Chief R&D Officer

Li Sun, MD, PhD; Former Professor of Medicine; Co-Director, Mount Sinai Bone Program – VP, Research

Advisors: TBD

Scientific Advisory Board: TBD

Number of Employees: 5

Finance:

Auditor: TBD

Financing Sought: \$1.2M

- Continuing preclinical studies
- Toxicology and pharmacokinetics
- Preparation for IND application
- IP

IP: Provisional patent application in preparation

Legal: TBD

Business Description / Company Background:

New York R&D Center for Translational Medicine and Therapeutics (Ny.TmT) is an R&D company pursuing commercialization of therapies addressing musculoskeletal diseases and disorders, such as tendinopathy and osteoarthritis. In particular, tendinopathy is a painful, chronic disease of the tendon with degeneration of the tissue and cellular structures, which often leads to tendon rupture. Current development of *miR-T1*, a novel microRNA-based therapeutic, that aims to provide a disease-modifying therapy for tendinopathy by restoring tendon function and alleviating pain.

Ny.TmT was founded in 2013 by Dr. Herb Sun, former Director of Orthopaedic Research and Professor of Orthopaedic Surgery at Albert Einstein College of Medicine.

Market Opportunity / Unmet Need:

Tendinopathy represents a common and significant clinical problem, affecting 30%-50% in people aged 60+ and many others in the occupational and physically-active populations. Examples of tendinopathy include jumper's knee and tennis elbow. It is identified as the most severe non-fatal illnesses in terms of work days lost. There is currently no cure; most nonsurgical treatments (i.e., NSAIDs) are intended to alleviate symptoms (e.g., pain), but do not address the disease pathophysiology. The initial target indication for the novel microRNA is treatment for tennis elbow, which alone is valued at \$4.5B globally and represents an obtainable market of >\$400M in the U.S. Growth rate.

Products / Services – Launched & Pipeline:

Ny.TmT pursues the long-term goal of commercialization of therapies for musculoskeletal diseases and techniques for enhanced surgical repair. Current platform development covers stem cell-based technologies, botanical formulations and purified drug, targeting both human and veterinary markets. The product pipeline is led by the current development of advanced therapy for tendinopathy, followed by an ongoing effort to pursue a novel treatment solution for osteoarthritis.

Commercial / Technical Milestones:

Achieved: miR-T1 therapy exhibited compelling evidence of disease modification with pain relief and restored tissue properties in a validated animal model of tendinopathy (Q4 2020). Ongoing: Continuing animal studies for dosing (Q2 2021). Pending: IP Filing (Q2 2021); GMP grade manufacturing capacity and infrastructure is under development (Q3 2021);

Competition / competitive Advantages / Customer Benefits:

Currently available treatments for tendinopathy tend to be conservative. NSAIDs and corticosteroids aim to alleviate pain-related symptoms. Biologics, such as platelet-rich plasma, remains controversial. Competitive technologies under development largely include autologous cell implantation and platelet-rich plasma-based biologics, which may be reparative. miR-T1 is unique in that it modifies the disease process by suppressing regulators and pathways for pathogenesis of tendinopathy, which translates clinically to restoration of tendon function and relief of symptoms. As an allogeneic therapy, miR-T1 is deliverable as an off-the-shelf injectable agent.

Financial Forecast:

Ny.TmT is not submitting a financial forecast at this time due to the early-stage nature of the development.